Marshall Fordyce - Jan 16, 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Jan 16, 2024
Transactions value $
$0
Form type
4
Date filed
1/18/2024, 04:54 PM
Previous filing
Jan 3, 2024
Next filing
Aug 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Award $0 +78.8K +30.66% $0.00 336K Jan 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Award $0 +293K $0.00 293K Jan 16, 2024 Class A Common Stock 293K $16.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date.
F2 1/48 of the shares subject to the stock option will vest and become exercisable on February 16, 2024, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.